Quanterix (NASDAQ:QTRX) Earns Sell (D-) Rating from Weiss Ratings

Quanterix (NASDAQ:QTRX)‘s stock had its “sell (d-)” rating restated by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, Canaccord Genuity Group reiterated a “hold” rating and set a $5.00 price objective (down previously from $12.00) on shares of Quanterix in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $11.75.

Quanterix Price Performance

NASDAQ:QTRX opened at $6.00 on Wednesday. The firm’s 50-day moving average price is $5.08 and its 200-day moving average price is $5.51. The company has a market capitalization of $278.82 million, a PE ratio of -3.30 and a beta of 1.07. Quanterix has a 1-year low of $4.05 and a 1-year high of $15.67.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.06). The firm had revenue of $24.48 million for the quarter, compared to analysts’ expectations of $29.73 million. Quanterix had a negative net margin of 56.04% and a negative return on equity of 18.41%. Quanterix has set its FY 2025 guidance at EPS. Equities analysts anticipate that Quanterix will post -0.98 EPS for the current fiscal year.

Institutional Trading of Quanterix

Large investors have recently made changes to their positions in the stock. SCS Capital Management LLC purchased a new stake in shares of Quanterix during the first quarter valued at $2,307,000. Cubist Systematic Strategies LLC acquired a new position in shares of Quanterix during the first quarter valued at about $1,870,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Quanterix during the first quarter valued at about $98,000. Invenomic Capital Management LP acquired a new position in shares of Quanterix during the first quarter valued at about $5,872,000. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Quanterix by 46.2% during the first quarter. Envestnet Asset Management Inc. now owns 500,398 shares of the company’s stock valued at $3,258,000 after acquiring an additional 158,134 shares in the last quarter. 86.48% of the stock is owned by hedge funds and other institutional investors.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.